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Problem statement
The research carried out aimed to encourage evidence-
based cost-effective pharmaceutical prescribing, reduce
medicine related adverse reactions, improve patient
quality of life and reduce pharmaceutical wastage. Prescrib-
ing data was evaluated and interventions were subsequently
developed in an attempt to improve pharmaceutical pre-
scribing by General Practitioners (GPs) across an enrolled
population.
Objectives
(1) To evaluate the effectiveness of interventions being
developed to optimise prescribing by GPs, (2) To recog-
nise factors affecting prescribing patterns of medicines
targeted by the programme, and (3) To identify other
medicines information sources which influence GP
prescribing.
Policy targeted(s): Pharmaceutical prescribing of medi-
cines, in particular medicines available funded through
the Pharmaceutical Management Agency (PHARMAC)
was evaluated to observe trends in prescribing. These
funded medicines are generally generics which are highly
accessible to populations in which they are necessary.
Stakeholder: ProCare Health NZ is a Primary Health
Organisation which was responsible for data collection
and recruiting GPs within its District Health Board.
Region covered: New Zealand WPRO, Region
number 13.
Method
Retrospective delay analysis of pharmaceutical data was
conducted using Excel to identify potential reductions in
expenditure and volume of targeted pharmaceuticals
and pharmaceuticals overall. A pilot prospective, cross-
sectional study investigating the perceptions held by GPs
regarding the influence of Optimising Prescribing inter-
ventions on their prescribing practices was also carried
out. Research was carried out over a two year period
(July 2009 to March 2011). An overview of methodology
and interventions used is shown in Figure 1.
Results
Some medicines showed changes in prescribing volume
and pharmaceutical expenditure in response to the
initiation of the interventions. For example, the prescrib-
ing volume of calcium carbonate in ProCare Network
Manukau and East Health dropped sharply after the
initiation of Optimising Prescribing interventions, which
consists of medicines information bulletins and cell
focus groups. However, the prescribing volume of
calcium carbonate in ProCare Network Auckland
declined before the intervention was initiated, implying
that there are other sources of influence involved. From
the pilot survey, Best Practice Advocacy Centre (BPAC)
was cited by GPs as the most influential source of
medicines information in their prescribing practice.
Conslusion
There is evidence, following the changes in pharmaceutical
expenditure and prescribing volume in some investigated
medicines. These show Optimising Prescribing interven-
tions to be effective in influencing GP prescribing practices.
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